F e t a l i n s u l i n is considered to be a n i n t r a u t e r i n e m prom t i n g h o m n e . I n t r a u t e r i n e m r e t a r d a t i o n h a s keen one of C o n t r o l s (C) i n c l u d e normal f u l l tern a p p r o p r i a t e f o r g e s t a t i o n a l a g e (A@.) and s m a l l f o r g e s t a t i o n a l a g e b a b i e s o f non-drug addicted mthers. G e s t a t i o n a l a g e was a s s e s s e d by DUBOWITZ and There is s i q n i f i c a n t d e c r e a s e in insulin l e v e s i n SGA n h m s a s c a p x e d to AGA group. The i n s u l i n l e v e l s of AGA-DA group are s i g n i f i c a n t l y 1-r than AGA-C b u t s i g n i f i c a n t l y h i g h e r than SGA-C or SGA-DA. I n s u l i n l e v e l s i n SGA-DA were s i g n i f i c a n t l y lower than in SGA-C. These r e s u l t s s u g q e s t t h a t i n t r a u t e r i n e In vitro, prolactin secretion but not release is influenced by media Ca. Prolactin homeostasis in VLBW infants and effect of neonatal HC on secretion and release of prolactin a r e unclear. In 6 preterm AGA neonates, birthwt. 1050 + 96 gms(rnean t sd), gestation '32 wks, we studied the theses: 1)serum prolactin would be high; 2)serum Ca <6.0 mg/dl would be associated with decline in serum prolactin; 3)Ca infusion would not affect prolactin release; but may increase prolactin secretion. Serum Ca, iCa, Mg, P, and prolactin were determined on entry; when serum Ca <6.0 mgldl; immediately post infusion of 18 mglkg of Ca a s 10% Ca gluconate over 10 minutes; +8 hrs post Ca infusion. Serum prolactin was determined by RIA (N 4 8 ng/ml in males, < 25 nglml in females).
Serum total Ca was 7.4 t0.2 a t 11 t 2.6 hrs of age, and declined t o 5.1 t0.2 mgldl (mean t se,p <0.025) a t 46 t 9 hrs and rose t o 9.2 t 0.7 and 7.1 t 0.5 mgldl immediately and +8 hrs post Ca infusion; serum iCa was 3.24 t 0.3, 3.8 f 0.2, 6.9 t0.6 and 4.2 + 0.2 mgldl a t these times, serum Mg and P d~d not change. Basal serum prolactin was elevated 209 f41 nglml (p < 0.05 vs adult control) and declined t o 121 i 23 ng/ml, p < 0.05, associated with hypocalcemia; immediately post Ca serum prolactin was 124 t 28 ng/ml and 129 f 2 0 nglrnl a t +8 hrs post Ca. Thus, in VLBW infants, I) serum prolactin is extremely high; 2) serum prolactin declines postnatally associated with decline in serum Ca low a s 5.0 mgldl; 3)in HC Ca infusion does not cause acute or subacute changes in serum prolactin. We speculate that although serum Ca and prolactin show similar temporal changes, serum Ca, low a s 5.0 mgldl with low serum iCa does not modify prolactin homeostasis.
HEMOGLOBIN LEVELS I N HYPOTHYROID INFANTS.
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C h i l d r e n a n d ' a i u l t i w i t h l o n g -s t a n d i n g h y p o t h y r b i d -
i s m f r e q u e n t l y d e v e l o p a n e m i a , o f t e n o f a m a c r o c y t i c n a t u r e . T h e i n c i d e n c e o f a n e m i a h a s b e e n r e p o r t e d t o b e b e t w e e n 21 a n d 61% i n a d u l t s . We i n v e s t i g a t e d newb o r n s w i t h h y p o t h y r o i d i s m f o r t h e p r e s e n c e o f a n e m i a . A l l i n f a n t s w e r e i n i t i a l l y d e t e r m i n e d t o h a v e a b n o r m a l t h y r o i d f u n c t i o n by t h e N . Y . S t a t e S c r e e n i n g P r o g r a m w i t h h e e l s t i c k b l o o d s p e c i m e n s o b t a i n e d by d a y 3 o f l i f e . Newborns w i t h e l e v a t e d TSH l e v e l s (>2O pU/ml) o r l o w Tq l e v e l s ((8 u g / d l ) w e r e i n c l u d e d i n t h e s t u d y . R e p e a t t h y r o i d s t u d i e s w e r e p e r f o r m e d a t 10 t o 55 d a y s o f l i f e , a n d b l o o d c o u n t s w i t h RBC i n d i c e s w e r e meas u r e d by C o u l t e r C o u n t e r . A l l c h i l d r e n w i t h o t h e r c a u s e s o f a n e m i a o r p o l y c y t h e m i a w e r e e x c l u d e d f r o m a n a l y s i s . Of 2 3 i n f a n t s who f i t t h e s e c r i t e r i a , n o n e w e r e f o u n d t o b e a n e m i c , The incidence of t r a n s i e n t hypothyroidism i n very low b i r t h weight i n f a n t s h a s not been d e l i n e a t e d . We s t u d i e d 22 premature i n f a n t s <lo00 grams and (30 weeks g e s t a t i o n . Eight i n f a n t s died w i t h i n four da-s and t h e i r d a t a excluded.
T4 The n a d i r of T4 and FT4 and t h e peak TSH l e v e l s occurred a t 2 weeks. Eight of 10 babies had T4's <6%/dl and 7 had FT4's <0.8ng/dl (helow accepted normal v a l u e s ) . No TSH value was >20plJ/ml. The FT4's were lower than a n t i c i p a t e d . These d a t a a r e compatible with t r a n s i e n t hypothyroxinemia. However, i t i s possi b l e t h a t t h e s e babies had t r a n s i e n t hypothyroidism with a blunted TSH response secondary t o immaturity of t h e hypothalamo-pituitary-thyroid a x i s . -.
ADRENARCHE AND GROWTH DURING LHRH AGONIST (LHRHa)
a502
During puberty t h e e f f e c t of a d r e n a l androgens on s k e l e t a l maturation and growth i s obscured by t h e i n f l u e n c e of gonadal s t e r o i d s . Suppression of gonadarche w i t h an LHRH, a f f o r d s an opportunity t o e x p l o r e t h e a s s o c i a t i o n between adrenarche,
s k e l e t a l development and a d u l t s t a t u r e . I n 16 g i r l s w i t h c e n t r a l precocious puberty (CPP), gonadarche was suppressed by LHRH, a d m i n i s t r a t i o n f o r 12 t o 36 months. During t r e a t m e n t dehydroepiandrosterone s u l f a t e (DS) l e v e l s , an index of adrenarche, were c o n s t a n t o r i n c r e a s e d i n an age expected fashion. Rate of bone maturation (&A) f o r change i n chronologic advancement (AcA) decreased a s shown by &A/ACA < 1 i n a l l s u b j e c t s . DS l e v e l s w e r e p o s i t i v e l y c o r r e l a t e d w i t h &A/ACA (R = 0.07, P < 0.002). S t a t u r a l growth a l s o decreased b u t l e s s than bone maturation s o t h a t p r e d i c t e d mature h e i g h t (Bayley and Pinneau) was i n c r e a s e d i n a l l b u t one s u b j e c t . A s i g n i f i c a n t n e g a t i v e l i n e a r r e g r e s s i o n of DS l e v e l s w i t h i n c r e a s e i n p r e d i c t e d h e i g h t was observed (R = -0.70, P < 0.003). Conclusions: 1) I n g i r l s w i t h CPP, adrenarche progressed during LHRHa suppression of gonadarche. 2) I n preadrenarchal g i r l s , LHRH, a d m i n i s t r a t i o n was a s s o c i a t e d with a more s t r i k i n g slowing of bone maturation w i t h r e l a t i v e l y l e s s e r e f f e c t s on h e i g h t v e l o c i t y . I n t h o s e g i r l s w i t h t h e o n s e t o r progression of adrenarche i n t h e absence of gonadal s t e r o i d s , therapy was a s s o c i a t e d with l e s s evidence of r e s t r a i n t on bone maturation. 3) These d a t a a r e compatible w i t h a d i r e c t e f f e c t of a d r e n a l androgens upon s k e l e t a l maturation and growth.
SUBCUTANEOUS VERSUS INTRAMUSCUIAR HUMAN GROWTB BORMONE THERAPY: GROWH AND ACUTE SOMATOMEDIN
503 RESPONSE. , Wilson. BK Baker, RL Hintz, and RG Rosenfeld,Stanford University, Dept. of P e d i a t r i c s , S t a n f o r d , CA Although growth hormone (GH) has t r a d i t i o n a l l y been administered intramuscularly (IM), concerns regarding p a t i e n t comfort and compliance have led t o t h e c o n s i d e r a t i o n of t h e subcutaneous (SQ) r o u t e . To compare SQ and I M a d m i n i s t r a t i o n of GH, we have examined t h e a c u t e i n s u l i n -l i k e growth f a c t o r I (IGF-I) & I1 response t o 4 d a i l y i n j e c t i o n s of G H (0.1 U/kg) i n 21 G H d e f i c i e n t c h i l d r e n . S u b j e c t s were o f f G H f o r a t l e a s t 2 weeks p r i o r t o randomization t o SQ (11) o r I M ( 1 0 ) . Samples were obtained a t b a s e l i n e and 20 h r a f t e r t h e 4 t h i n j e c t i o n . IGF-I and IGF-I1 were measured by s p e c f i c RIAs. Growth r a t e and antibody l e v e l s were determined b e f o r e and a f t e r 6 months of t h r e e times a week therapy. W e evaluated parent and s u b j e c t preference i n those who switched t o SQ by questionnaire. IGF-I l e v e l s t r i p l e d a f t e r 4 days of G H i n both groups (43558 (+SD) t o 1 4 9 9 0 6 nglml SQ, 435 27 t o 144265 IM) while IGF-I1 l e v e l s n e a r l y doubled ( 5 3 7~3 2 6 t o 10145332 ng/ml SQ, 6175394 t o 10882426 IM). I n those who had completed 6 months of therapy, t h e r e was no s i g n i f i c a n t d i f f e r e n c e i n t h e growth r a t e s (5.043.26 cm/yr SQ, 6 . 7 2 9 . 0 9 cmlyr IM) and only one p a t i e n t developed G H a n t i b o d i e s (IM group). Both p a r e n t s and s u b j e c t s expressed a s t r o n g p r e f e r e n c e f o r t h e SQ method ( 8 of 9 thought SQ b e t t e r than o r equal t o IN). The i d e n t i c a l r i s e s of both IGF-I and IGF-I1 following a b r i e f course of e i t h e r SQ o r I M GH, t h e s i m i l a r growth r a t e s and lack of antibody development a l l suggest t h a t t h e two r o u t e s a r e e q u i v a l e n t , while p a t i e n t s and p a r e n t s c l e a r l y p r e f e r SQ therapy.
